The reform of the pharmaceutical industry is intensifying, and the work of the senior management is frequently transferred

In recent years, under the influence of medical reform policies such as centralized procurement, medical insurance, "drug ratio", and "prescription anti-corruption", the reform of the pharmaceutical industry has intensified, and the accompanying changes in the executives of pharmaceutical companies are also very frequent
.
Judging from the reasons for resignation, many executives resigned due to personal reasons, but there are also a number of them due to job transfer
.
Recently, there have been many executives who have resigned due to job transfer
.
For example, ST Muyao announced on the evening of April 1 that Mr.
Weng Xiangyang applied to resign from the position of deputy general manager of the company due to job adjustment
.
On the same day, Mr.
Wang Peijun applied for his resignation as the company's deputy general manager due to personal reasons; Mr.
Geng Min applied for his resignation as the company's deputy general manager due to physical reasons
.
After resigning, the three continued to hold other positions at the company
.
According to the data, ST's main business is pharmaceutical manufacturing and pharmaceutical distribution
.
On March 29, Hualan Biology issued an announcement that the board of directors recently received written resignation reports from the company's senior executives, Wang Qiping, An Wenqi, and Pan Ruowen.
Among them, Wang Qiping resigned as deputy general manager of the company due to retirement; An Wenqi and Pan Ruowen She resigned from the position of deputy general manager of the company due to job changes.
Among them, Ms.
An Wenqi has been nominated as the company's director candidate, and Ms.
Pan Ruowen has been nominated as the company's director candidate, and plans to hold relevant positions in the holding subsidiary
.
According to the data, Hualan Bio is mainly engaged in the research and development, production and sales of blood products, vaccines and genetically engineered products
.
On March 31, Weili Medical announced that the board of directors of the company recently received a written resignation report from Huang An, the company's deputy general manager.
Huang An applied for his resignation as the company's deputy general manager due to work adjustment reasons
.
According to the data, Weili Medical is mainly engaged in the research and development, production and sales of medical devices in the fields of anesthesia, urology, nursing, breathing, and hemodialysis
.
On the evening of March 23, China Pharmaceutical announced that recently, the company's board of supervisors received a written resignation letter from Chen Zheng.
Due to work adjustment, Chen Zheng applied to resign as a supervisor of the company and no longer held any positions in the company
.
The company's business scope includes wholesale of Chinese patent medicines, Chinese herbal medicines, Chinese herbal decoction pieces, chemical pharmaceutical preparations, chemical raw materials, etc.

.
On February 14, China Resources Shuanghe announced that due to work arrangements, Han Yuewei applied for his resignation as a director of the company's ninth board of directors and a member of special committees
.
According to the data, the business of China Resources Double Crane focuses on chronic disease business, specialist business and infusion business
.
On January 4, Tigermed announced that the board of directors of the company recently received a written resignation report from deputy general manager Wang Ruwei.
Wang Ruwei applied for his resignation as deputy general manager of the company due to job transfer
.
According to relevant regulations, Wang Ruwei's resignation will take effect when the resignation report is delivered to the board of directors
.
After Wang Ruwei resigned as the company's deputy general manager, he still held other positions in the company's subsidiaries
.
According to the announcement, Wang Ruwei's departure will not affect the normal operation of the company
.
According to the data, Tigermed mainly provides professional services for the whole process of clinical research of innovative drugs, medical devices and biotechnology-related products for domestic and foreign pharmaceutical and medical device innovation enterprises
.
From the perspective of the industry, behind the frequent transfer of senior management of pharmaceutical companies is the response and adjustment of various pharmaceutical companies to the changes in the Chinese pharmaceutical market environment
.
At present, pharmaceutical companies are generally facing the pressure of transformation and upgrading, sales compliance and other aspects of survival, and the management of the company is also under direct pressure.
Whether it is strategic thinking or tactical application, they need to break the inherent thinking and find future breakthroughs in the industry point
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.